Burning Rock Biotech Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.05
- Today's High:
- $1.18
- Open Price:
- $1.07
- 52W Low:
- $1.7
- 52W High:
- $4.24
- Prev. Close:
- $1.09
- Volume:
- 86283
Company Statistics
- Market Cap.:
- $242.31 million
- Book Value:
- 11.285
- Revenue TTM:
- $563.24 million
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $380.04 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -31.7%
- Return on Equity TTM:
- -64.67%
Company Profile
Burning Rock Biotech Ltd had its IPO on 2020-06-12 under the ticker symbol BNR.
The company operates in the Healthcare sector and Diagnostics & Research industry. Burning Rock Biotech Ltd has a staff strength of 1,138 employees.
Stock update
Shares of Burning Rock Biotech Ltd opened at $1.07 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.05 - $1.18, and closed at $1.12.
This is a +2.75% increase from the previous day's closing price.
A total volume of 86,283 shares were traded at the close of the day’s session.
In the last one week, shares of Burning Rock Biotech Ltd have slipped by -18.25%.
Burning Rock Biotech Ltd's Key Ratios
Burning Rock Biotech Ltd has a market cap of $242.31 million, indicating a price to book ratio of 1.545 and a price to sales ratio of 0.5153.
In the last 12-months Burning Rock Biotech Ltd’s revenue was $563.24 million with a gross profit of $380.04 million and an EBITDA of $-859660032. The EBITDA ratio measures Burning Rock Biotech Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Burning Rock Biotech Ltd’s operating margin was 0% while its return on assets stood at -31.7% with a return of equity of -64.67%.
In Q1, Burning Rock Biotech Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 3.5%.
Burning Rock Biotech Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Burning Rock Biotech Ltd’s profitability.
Burning Rock Biotech Ltd stock is trading at a EV to sales ratio of 0.2669 and a EV to EBITDA ratio of -0.1494. Its price to sales ratio in the trailing 12-months stood at 0.5153.
Burning Rock Biotech Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.42 billion
- Total Liabilities
- $358.12 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Burning Rock Biotech Ltd ended 2024 with $1.42 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.42 billion while shareholder equity stood at $1.05 billion.
Burning Rock Biotech Ltd ended 2024 with $0 in deferred long-term liabilities, $358.12 million in other current liabilities, 138000.00 in common stock, $-3385199000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $793.48 million and cash and short-term investments were $793.48 million. The company’s total short-term debt was $32,312,000 while long-term debt stood at $0.
Burning Rock Biotech Ltd’s total current assets stands at $1.14 billion while long-term investments were $599000.00 and short-term investments were $0. Its net receivables were $174.44 million compared to accounts payable of $23.59 million and inventory worth $113.90 million.
In 2024, Burning Rock Biotech Ltd's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Burning Rock Biotech Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.12
- 52-Week High
- $4.24
- 52-Week Low
- $1.7
- Analyst Target Price
- $5.54
Burning Rock Biotech Ltd stock is currently trading at $1.12 per share. It touched a 52-week high of $4.24 and a 52-week low of $4.24. Analysts tracking the stock have a 12-month average target price of $5.54.
Its 50-day moving average was $1.71 and 200-day moving average was $2.5 The short ratio stood at 21.63 indicating a short percent outstanding of 0%.
Around 603.8% of the company’s stock are held by insiders while 5954.1% are held by institutions.
Frequently Asked Questions About Burning Rock Biotech Ltd
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People’s Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.